These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12756880)

  • 21. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
    Finch A; Shaw P; Rosen B; Murphy J; Narod SA; Colgan TJ
    Gynecol Oncol; 2006 Jan; 100(1):58-64. PubMed ID: 16137750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Familial history of ovarian carcinoma: policy].
    de Hullu JA; Kets CM; Massuger LF; Ligtenberg ML; van Ham MA; Hoogerbrugge N
    Ned Tijdschr Geneeskd; 2011; 155():A2392. PubMed ID: 21262027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
    Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
    Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
    Kauff ND; Barakat RR
    Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933
    [No Abstract]   [Full Text] [Related]  

  • 25. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
    Callahan MJ; Crum CP; Medeiros F; Kindelberger DW; Elvin JA; Garber JE; Feltmate CM; Berkowitz RS; Muto MG
    J Clin Oncol; 2007 Sep; 25(25):3985-90. PubMed ID: 17761984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In cases of familial ovarian cancer, always consider the risk of breast cancer].
    Kets CM; Niermeijer MF; Massuger LF; Hoogerbrugge N
    Ned Tijdschr Geneeskd; 2004 Aug; 148(35):1709-11. PubMed ID: 15468897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
    Olivier RI; van Beurden M
    Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
    [No Abstract]   [Full Text] [Related]  

  • 28. Prophylactic oophorectomy in women at increased cancer risk.
    Domchek SM; Rebbeck TR
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening--A case report.
    Hill KA; Rosen B; Shaw P; Causer PA; Warner E
    Gynecol Oncol; 2007 Oct; 107(1):136-9. PubMed ID: 17629551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer.
    Chand M; Moore PJ; Clarke AD; Nash GF; Hickisk T
    World J Surg Oncol; 2007 Sep; 5():102. PubMed ID: 17850658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.
    Vicus D; Shaw PA; Finch A; Rosen B; Murphy J; Armel S; Sun P; Narod SA
    Gynecol Oncol; 2010 Sep; 118(3):295-8. PubMed ID: 20722102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.
    Haber D
    N Engl J Med; 2002 May; 346(21):1660-2. PubMed ID: 12024000
    [No Abstract]   [Full Text] [Related]  

  • 33. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
    J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level?
    van Altena AM; Holtsema H; Hendriks JC; Massuger LF; de Hullu JA
    Menopause; 2011 Feb; 18(2):133-7. PubMed ID: 20861755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
    Mingels MJ; Roelofsen T; van der Laak JA; de Hullu JA; van Ham MA; Massuger LF; Bulten J; Bol M
    Gynecol Oncol; 2012 Oct; 127(1):88-93. PubMed ID: 22710074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Women harboring BRCA1/2 germline mutations are at risk for breast and female adnexal carcinoma.
    Piek JM; Dorsman JC; Zweemer RP; Verheijen RH; van Diest PJ; Colgan TJ
    Int J Gynecol Pathol; 2003 Jul; 22(3):315-6; author reply 315-6. PubMed ID: 12819403
    [No Abstract]   [Full Text] [Related]  

  • 38. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy.
    Hirst JE; Gard GB; McIllroy K; Nevell D; Field M
    Int J Gynecol Cancer; 2009 Jul; 19(5):826-9. PubMed ID: 19574767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?
    Cass I; Walts A; Karlan BY
    Gynecol Oncol; 2010 Apr; 117(1):27-31. PubMed ID: 20110118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
    Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
    J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.